BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28233220)

  • 1. Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.
    Vanan MI; Underhill DA; Eisenstat DD
    Neurotherapeutics; 2017 Apr; 14(2):274-283. PubMed ID: 28233220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of H3 K27M mutations in adult midline gliomas.
    Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Grade Gemistocytic Morphology in H3 G34R-Mutant Gliomas and Concurrent K27M Mutation: Clinicopathologic Findings.
    Morris M; Driscoll M; Henson JW; Cobbs C; Jiang L; Gocke CD; Chen L; Rodriguez FJ
    J Neuropathol Exp Neurol; 2020 Oct; 79(10):1038-1043. PubMed ID: 32954438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
    Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
    Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
    Fontebasso AM; Schwartzentruber J; Khuong-Quang DA; Liu XY; Sturm D; Korshunov A; Jones DT; Witt H; Kool M; Albrecht S; Fleming A; Hadjadj D; Busche S; Lepage P; Montpetit A; Staffa A; Gerges N; Zakrzewska M; Zakrzewski K; Liberski PP; Hauser P; Garami M; Klekner A; Bognar L; Zadeh G; Faury D; Pfister SM; Jabado N; Majewski J
    Acta Neuropathol; 2013 May; 125(5):659-69. PubMed ID: 23417712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
    Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
    J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H3F3A K27M mutations in thalamic gliomas from young adult patients.
    Aihara K; Mukasa A; Gotoh K; Saito K; Nagae G; Tsuji S; Tatsuno K; Yamamoto S; Takayanagi S; Narita Y; Shibui S; Aburatani H; Saito N
    Neuro Oncol; 2014 Jan; 16(1):140-6. PubMed ID: 24285547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial.
    Rodriguez Gutierrez D; Jones C; Varlet P; Mackay A; Warren D; Warmuth-Metz M; Aliaga ES; Calmon R; Hargrave DR; Cañete A; Massimino M; Azizi AA; Le Deley MC; Saran F; Rousseau RF; Zahlmann G; Garcia J; Vassal G; Grill J; Morgan PS; Jaspan T
    Clin Cancer Res; 2020 Apr; 26(8):1856-1865. PubMed ID: 31924736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone H3 K27M mutations in adult cerebellar high-grade gliomas.
    Nakata S; Nobusawa S; Yamazaki T; Osawa T; Horiguchi K; Hashiba Y; Yaoita H; Matsumura N; Ikota H; Hirato J; Yoshimoto Y; Yokoo H
    Brain Tumor Pathol; 2017 Jul; 34(3):113-119. PubMed ID: 28547652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
    Deng H; Zeng J; Zhang T; Gong L; Zhang H; Cheung E; Jones C; Li G
    Mol Cancer Res; 2018 Apr; 16(4):623-633. PubMed ID: 29453317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncohistones and disrupted development in pediatric-type diffuse high-grade glioma.
    Ocasio JK; Budd KM; Roach JT; Andrews JM; Baker SJ
    Cancer Metastasis Rev; 2023 Jun; 42(2):367-388. PubMed ID: 37119408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating H3F3A K27M and G34R/V somatic mutations in a cohort of pediatric brain tumors of different and rare histologies.
    Oliveira VF; De Sousa GR; Dos Santos AC; Saggioro FP; Machado HR; de Oliveira RS; Tone LG; Valera ET
    Childs Nerv Syst; 2021 Feb; 37(2):375-382. PubMed ID: 32766947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.
    Huang TY; Piunti A; Lulla RR; Qi J; Horbinski CM; Tomita T; James CD; Shilatifard A; Saratsis AM
    Acta Neuropathol Commun; 2017 Apr; 5(1):28. PubMed ID: 28416018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
    Sangatsuda Y; Miura F; Araki H; Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Arai Y; Yoshida A; Shibata T; Yoshimoto K; Iihara K; Ito T
    Sci Rep; 2020 Sep; 10(1):16162. PubMed ID: 32999376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
    Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
    Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.
    Lee J; Solomon DA; Tihan T
    J Neurooncol; 2017 Mar; 132(1):1-11. PubMed ID: 28064387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
    Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
    Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression.
    Lopez GY; Oberheim Bush NA; Phillips JJ; Bouffard JP; Moshel YA; Jaeckle K; Kleinschmidt-DeMasters BK; Rosenblum MK; Perry A; Solomon DA
    Acta Neuropathol; 2017 Dec; 134(6):961-963. PubMed ID: 29063183
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.